Publications of Institute of Radiopharmaceutical Cancer Research

68 Publications

2023

Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide and Main Group Metal Ions

Kopp, I.; Cieslik, P.; Anger, K.; Josephy, T.; Neupert, L.; Velmurugan, G.; Gast, M.; Wadepohl, H.; Brühlmann, S. A.; Walther, M.; Kopka, K.; Bachmann, M.; Stephan, H.; Kubeil, M.; Comba, P.

Lysyl oxidases as targets for cancer therapy and diagnostic imaging

Löser, R.; Kuchar, M.; Wodtke, R.; Neuber, C.; Belter, B.; Kopka, K.; Santhanam, L.; Pietzsch, J.

Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1

Krutzek, F.; Donat, C.; Ullrich, M.; Zarschler, K.; Ludik, M.-C.; Feldmann, A.; Rodrigues Loureiro, L. R.; Kopka, K.; Stadlbauer, S.

Related publications

Development of the High-Affinity Carborane-Based Cannabinoid Receptor Type 2 PET Ligand [18F]LUZ5-d8

Ueberham, L.; Gündel, D.; Kellert, M.; Deuther-Conrad, W.; Ludwig, F.-A.; Lönnecke, P.; Kazimir, A.; Kopka, K.; Brust, P.; Moldovan, R.-P.; Hey-Hawkins, E.

Radiofluorination of an anionic, azide-functionalized teroligomer by copper-catalyzed azide-alkyne cycloaddition

Wenzel, B.; Schmid, M.; Teodoro, R.; Moldovan, R.-P.; Lai, T. H.; Mitrach, F.; Kopka, K.; Fischer, B.; Schulz-Siegmund, M.; Brust, P.; Hacker, M. C.

Synthesis of [18F]FMISO, a hypoxia-specific imaging probe for PET, an overview from a radiochemist’s perspective

Knieß, T.; Zessin, J.; Mäding, P.; Kuchar, M.; Kiß, O.; Kopka, K.

Cyclotron-based Production of 67Cu for Radionuclide Theranostics Via the 70Zn(p,α)67Cu Reaction

Brühlmann, S. A.; Walther, M.; Kreller, M.; Reissig, F.; Pietzsch, H.-J.; Knieß, T.; Kopka, K.

Efforts towards PET-activatable red-shifted silicon rhodamines and silicon pyronine dyes

Kramer, C. S.; Kanagasundaram, T.; Matthias, J.; Kopka, K.

Copper-free click bioconjugation of technetium-99m complexes using strained cyclononyne derivatives

Schlesinger, M.; Jentschel, C.; Pietzsch, H.-J.; Kopka, K.; Mamat, C.

DGN-Handlungsempfehlung (S1-Leitlinie) PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms Stand: 01/2022 AWMF-Registernummer: 031-055

Afshar-Oromieh, A.; Eiber, M.; Fendler, W.; Schmidt, M.; Rahbar, K.; Ahmadzadehfar, H.; Umutlu, L.; Hadaschik, B.; Hakenberg, O.; Fornara, P.; Kurth, J.; Neels, O.; Wester, H.-J.; Schwaiger, M.; Kopka, K.; Haberkorn, U.; Herrmann, K.; Krause, B.

Improved protocol for the radiosynthesis of [18F]FTC-146: A potent and selective sigma-1 receptor radioligand

Sadeghzadeh, M.; Wenzel, B.; Nikodemus, J.; Florea, A.; Hertel, F.; Kopka, K.; Vogg, A.; Kiessling, F.; Mottaghy, F. M.

  • Open Access Logo Journal of Labelled Compounds and Radiopharmaceuticals 66(2023)3, 116-125
    DOI: 10.1002/jlcr.4018

Enzymological characterization of ⁶⁴Cu-labeled neprilysin substrates and their application for modulating the renal clearance of targeted radiopharmaceuticals

Brandt, F.; Ullrich, M.; Wodtke, J.; Kopka, K.; Bachmann, M.; Löser, R.; Pietzsch, J.; Pietzsch, H.-J.; Wodtke, R.

Related publications

Dipeptide-derived alkynes as potent and selective irreversible inhibitors of cysteine cathepsins

Behring, L.; Ruiz-Gomez, G.; Trapp, C.; Morales, M.; Wodtke, R.; Köckerling, M.; Kopka, K.; Pisabarro, M. T.; Pietzsch, J.; Löser, R.

Related publications

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models

Ullrich, M.; Richter, S.; Liers, J.; Drukewitz, S.; Friedemann, M.; Kotzerke, J.; Ziegler, C. G.; Nölting, S.; Kopka, K.; Pietzsch, J.

2022

Towards personalized medicine: one chelator for imaging and therapy with lutetium-177 and actinium-225

Cieslik, P.; Kubeil, M.; Zarschler, K.; Ullrich, M.; Brandt, F.; Anger, K.; Wadepohl, H.; Kopka, K.; Bachmann, M.; Pietzsch, J.; Stephan, H.; Comba, P.

Related publications

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617.

Dos, S. J.; Schäfer, M.; Bauder-Wüst, U.; Beijer, B.; Eder, M.; Leotta, K.; Kleist, C.; Meyer, J.; Dilling, T.; Lewis, J.; Kratochwil, C.; Kopka, K.; Haberkorn, U.; Mier, W.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Toyohara, J.; Al-Qahtani, M.; Huang, Y.; Cazzola, E.; Todde, S.; Furumoto, S.; Mikolajczak, R.; Decristoforo, C.; Gillings, N.; Yang, M.; Reilly, R.; Duatti, A.; Denkova, A.; Schirrmacher, R.; Carlucci, G.; Seimbille, Y.; Liu, Z.; Ellis, B.; Cornelissen, B.; Kopka, K.; Bernardes, E.

Efficient Production of the PET radionuclide 133La for Theranostic Purposes in Targeted Alpha Therapy using the 134Ba(p,2n)133La Reaction

Brühlmann, S. A.; Kreller, M.; Pietzsch, H.-J.; Kopka, K.; Mamat, C.; Walther, M.; Reissig, F.

Radiosynthesis and preclinical evaluation of an 18F-labeled tri-azolopyridopyrazine-based inhibitor for neuroimaging of the phosphodiesterase 2A (PDE2A)

Wenzel, B.; Fritzsche, S. R.; Toussaint, M.; Briel, D.; Kopka, K.; Brust, P.; Scheunemann, M.; Deuther-Conrad, W.

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis

Krutzek, F.; Kopka, K.; Stadlbauer, S.

Fluorination of silyl prosthetic groups by fluorine mediated silyl ether linker cleavage: a concept study with conditions applicable in radiofluorination

Kramer, C. S.; Greiner, L.; Kopka, K.; Schäfer, M.

Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin

Reissig, F.; Zarschler, K.; Novy, Z.; Petrik, M.; Bendova, K.; Kurfurstova, D.; Bouchal, J.; Ludik, M.-C.; Brandt, F.; Kopka, K.; Khoylou, M.; Pietzsch, H.-J.; Hajduch, M.; Mamat, C.

Novel radioiodinated and radiofluorinated analogues of FT-2102 for SPECT or PET imaging of mIDH1 mutant tumours

Weber, V.; Arnaud, L.; Dukic-Stefanovic, S.; Wenzel, B.; Roux, V.; Chezal, J.-M.; Hang Lai, T.; Teodoro, R.; Kopka, K.; Miot-Noirault, E.; Deuther-Conrad, W.; Maisonial-Besset, A.

Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors

Liolios, C.; Patsis, C.; Lambrinidis, G.; Tzortzini, E.; Roscher, M.; Bauder-Wüst, U.; Kolocouris, A.; Kopka, K.

Radiopharmazie des vergangenen Jahrzehnts

Steinbach, J.; Kopka, K.

Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives

Kubeil, M.; Santana Martinez, I. I.; Bachmann, M.; Kopka, K.; Tuck L., K.; Stephan, H.

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer

Eder, A.; Matthias, J.; Schäfer, M.; Schmidt, J.; Steinacker, N.; Bauder-Wüst, U.; Domogalla, L.; Roscher, M.; Haberkorn, U.; Eder, M.; Kopka, K.

Experimental techniques to study protein–surfactant interactions: New insights into competitive adsorptions via drop subphase and Interface exchange

Javadi, A.; Dowlati, S.; Shourni, S.; Miller, R.; Kraume, M.; Kopka, K.; Eckert, K.

Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [¹⁸F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain

Clauß, O.; Schäker-Hübner, L.; Wenzel, B.; Toussaint, M.; Deuther-Conrad, W.; Gündel, D.; Teodoro, R.; Dukic-Stefanovic, S.; Ludwig, F.-A.; Kopka, K.; Brust, P.; Hansen, F. K.; Scheunemann, M.

Related publications

11C-Methionine Uptake in the Lactating Human Breast

Michler, E.; Hilliger, S.; Kopka, K.; Kotzerke, J.

Structure-Based Design, Optimization and Development of [18F]LU13, a novel radioligand for CB2R Imaging in the Brain with PET

Gündel, D.; Deuther-Conrad, W.; Ueberham, L.; Kaur, S.; Otikova, E.; Teodoro, R.; Lai, T. H.; Clauß, O.; Scheunemann, M.; Bormans, G.; Bachmann, M.; Kopka, K.; Brust, P.; Moldovan, R.-P.

Related publications

Cyclotrons operated for Nuclear Medicine and Radiopharmacy in the German speaking D-A-CH countries: An update on current status and trends

Zippel, C.; Ermert, J.; Patt, M.; Gildehaus, F. J.; Ross, T. L.; Reischl, G.; Neumaier, B.; Kiß, O.; Mitterhauser, M.; Wadsak, W.; Schibli, R.; Kopka, K.

Automated radiosynthesis of the adenosine A2A receptor-targeting radiotracer [18F]FLUDA

Lai, T. H.; Wenzel, B.; Moldovan, R.-P.; Brust, P.; Kopka, K.; Teodoro, R.

Related publications

  • Open Access Logo Journal of Labelled Compounds and Radiopharmaceuticals 65(2022), 162-166
    Online First (2022) DOI: 10.1002/jlcr.3970

Non-invasive assessment of locally overexpressed human adenosine 2A receptors in the heart of transgenic mice

Gündel, D.; Lai, T. H.; Dukic-Stefanovic, S.; Teodoro, R.; Deuther-Conrad, W.; Toussaint, M.; Moldovan, R.-P.; Kopka, K.; Boknik, P.; Hofmann, B.; Gergs, U.; Neumann, J.; Brust, P.

Related publications

“Clickable” albumin binders for modulating the tumor uptake of targeted radiopharmaceuticals

Brandt, F.; Ullrich, M.; Laube, M.; Kopka, K.; Bachmann, M.; Löser, R.; Pietzsch, J.; Pietzsch, H.-J.; van den Hoff, J.; Wodtke, R.

Related publications

Towards Optimized Bioavailability of 99mTc‑Labeled Barbiturates for Non‑invasive Imaging of Matrix Metalloproteinase Activity

Honold, L.; Austrup, M.; Faust, A.; Konken, C.; Schwegmann, K.; Zinnhardt, B.; Daniliuc, C.; Haufe, G.; Schäfers, M.; Kopka, K.; Hermann, S.

2021

Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.

Eder, A.; Schäfer, M.; Schmidt, J.; Bauder-Wüst, U.; Roscher, M.; Leotta, K.; Haberkorn, U.; Kopka, K.; Eder, M.

Radiolabeled Silicon-Rhodamines as Bimodal PET/SPECT-NIR Imaging Agents

Kanagasundaram, T.; Laube, M.; Wodtke, J.; Kramer, S. C.; Stadlbauer, S.; Pietzsch, J.; Kopka, K.

Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis.

Hoberück, S.; Löck, S.; Borkowetz, A.; Sommer, U.; Winzer, R.; Zöphel, K.; Fedders, D.; Michler, E.; Kotzerke, J.; Kopka, K.; Hölscher, T.; Braune, A.

Radiolabeled PSMA inhibitors

Neels, O.; Kopka, K.; Liolios, C.; Afshar-Oromieh, A.

Pharmacokinetic studies of [⁶⁸Ga]Ga‑PSMA‑11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type

Strauss, D. S.; Sachpekidis, C.; Kopka, K.; Pan, L.; Haberkorn, U.; Dimitrakopoulou‑Strauss, A.

Aktuelle Entwicklungen aus den Radiopharmazeutischen Wissenschaften für theranostische Anwendungen - Editorial

Mamat, C.; Kopka, K.

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.

Koerber, S.; Boesch, J.; Kratochwil, C.; Schlampp, I.; Ristau, J.; Winter, E.; Zschaebitz, S.; Hofer, L.; Herfarth, K.; Kopka, K.; Holland-Letz, T.; Jaeger, D.; Hohenfellner, M.; Haberkorn, U.; Debus, J.; Giesel, F.

Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer

Katzschmann, I.; Marx, H.; Kopka, K.; Hennrich, U.

Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-toproduce Ga-radiopharmaceutical kits and imaging probes

Klika, K.; Da, P. C.; Kopka, K.; Smith, G.; Makarem, A.

Development of an 18F-labelled irreversible inhibitor of transglutaminase 2 as radiometric tool for quantitative expression profiling in cells and tissues

Wodtke, R.; Wodtke, J.; Hauser, S.; Laube, M.; Bauer, D.; Rothe, R.; Neuber, C.; Pietsch, M.; Kopka, K.; Pietzsch, J.; Löser, R.

Related publications

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Aime, S.; Al-Qahtani, M.; Behe, M.; Bormans, G.; Carlucci, G.; Dasilva, J.; Decristoforo, C.; Duatti, A.; Elsinga, P.; Kopka, K.; Li, X.; Liu, Z.; Mach, R.; Middel, O.; Passchier, J.; Patt, M.; Penuelas, I.; Rey, A.; Scott, P.; Todde, S.; Toyohara, J.; Vugts, D.; Yang, Z.

Towards Targeted Alpha Therapy with Actinium 225: Chelators for Mild Condition Radiolabeling and Targeting PSMA – a Proof of Concept Study

Reissig, F.; Bauer, D.; Zarschler, K.; Novy, Z.; Bendova, K.; Kopka, K.; Pietzsch, H.-J.; Petrik, M.; Mamat, C.

Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies.

Matthias, J.; Engelhardt, J.; Schäfer, M.; Bauder-Wüst, U.; Meyer, P.; Haberkorn, U.; Eder, M.; Kopka, K.; Hell, S.; Eder, A.

The Impact of Barium Isotopes in Radiopharmacy and Nuclear Medicine – from Past to Presence

Reissig, F.; Kopka, K.; Mamat, C.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020).

Al-Qahtani, M.; Behe, M.; Bormans, G.; Carlucci, G.; Dasilva, J.; Decristoforo, C.; Elsinga, P.; Kopka, K.; Li, X.; Mach, R.; Middel, O.; Passchier, J.; Patt, M.; Penuelas, I.; Rey, A.; Scott, P.; Todde, S.; Toyohara, J.; Vugts, D.

Die Bedeutung des Elementes Barium in der Nuklearmedizin

Reissig, F.; Kopka, K.; Mamat, C.

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Eder, A.; Omrane, M.; Stadlbauer, S.; Roscher, M.; Khoder, W.; Gratzke, C.; Kopka, K.; Eder, M.; Meyer, P.; Jilg, C.; Ruf, J.

Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors

Wagner, S.; De, M. G. F.; Silva, D.; Ortiz, Z. N.; Zweemer, A.; Hermann, S.; De, M. M.; Koch, M.; Weiss, C.; Schepmann, D.; Heitman, L.; Tschammer, N.; Kopka, K.; Junker, A.

On the consensus nomenclature rules for radiopharmaceutical chemistry – reconsideration of radiochemical conversion

Herth, M.; Ametamey, S.; Antuganov, D.; Bauman, A.; Berndt, M.; Brooks, A.; Bormans, G.; Choe, Y.; Gillings, N.; Häfeli, U.; James, M.; Kopka, K.; Kramer, V.; Krasikova, R.; Madsen, J.; Mu, L.; Neumaier, B.; Piel, M.; Rösch, F.; Ross, T.; Schibli, R.; Scott, P.; Shalgunov, V.; Vasdev, N.; Wadsak, W.; Zeglis, B.

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

Koerber, S. A.; Sprute, K.; Kratochwil, C.; Winter, E.; Haefner, M. F.; Katayama, S.; Schlampp, I.; Herfarth, K.; Kopka, K.; Afshar-Oromieh, A.; Zschaebitz, S.; Holland-Letz, T.; Choyke, P. L.; Jaeger, D.; Hohenfellner, M.; Haberkorn, U.; Debus, J.; Giesel, F. L.

2020

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues

Sinnes, J.; Bauder-Wüst, U.; Schäfer, M.; Moon, E.; Kopka, K.; Rösch, F.

Development of PSMA-1007 - Related Series of 18F-Labeled Glu-ureido type PSMA inhibitors.

Cardinale, J.; Roscher, M.; Schaefer, M.; Geerlings, M.; Benešová, M.; Bauder-Wüst, U.; Remde, Y.; Eder, M.; Novakova, Z.; Motlová, L.; Bařinka, C.; Giesel, F.; Kopka, K.

Live-cell Imaging with Aspergillus Fumigatus-specific fluorescent Siderophore Conjugates

Pfister, J.; Lichius, A.; Summer, D.; Haas, H.; Kanagasundaram, T.; Kopka, K.; Decristoforo, C.

Synthesis, characterization and evaluation of 68Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor

Liolios, C.; Shegani, A.; Roupa, I.; Kiritsis, C.; Makarem, A.; Paravatou-Petsotas, M.; Pelecanou, M.; Bouziotis, P.; Papadopoulos, M.; Kopka, K.; Pirmettis, I.

Recent insights in barium-131 as a diagnostic match for radium-223: cyclotron production, separation, labeling and imaging

Reissig, F.; Bauer, D.; Ullrich, M.; Kreller, M.; Pietzsch, J.; Mamat, C.; Kopka, K.; Pietzsch, H.-J.; Walther, M.

Deuteration versus ethylation – strategies to improve the metabolic fate of a 18F-labeled celecoxib derivative

Laube, M.; Gassner, C.; Neuber, C.; Wodtke, R.; Ullrich, M.; Haase-Kohn, C.; Löser, R.; Köckerling, M.; Kopka, K.; Knieß, T.; Hey-Hawkins, E.; Pietzsch, J.

Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination

Naka, S.; Watabe, T.; Kurimoto, K.; Uemura, M.; Soeda, F.; Neels, O.; Kopka, K.; Tatsumi, M.; Kato, H.; Nonomura, N.; Shimosegawa, E.; Cardinale, J.; Giesel, F.; Hatazawa, J.

Rhenium and technetium-complexed silicon rhodamines as near-infrared imaging probes for bimodal SPECT- and optical imaging

Kanagasundaram, T.; Kramer, C. S.; Boros, E.; Kopka, K.

Interprofessionelle Kooperation in klinischen Studien. Zunehmender Bedarf, Komplexität und Anregungen am Beispiel einer prospektiv-onkologischen Multicenter-Studie.

Zippel, C.; Giesel, F.; Kopka, K.

Sub-10 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy

Reissig, F.; Zarschler, K.; Hübner, R.; Pietzsch, H.-J.; Kopka, K.; Mamat, C.

Current status of PSMA-radiotracers for prostate cancer: data analysis of prospective trials listed on ClinicalTrials.gov

Zippel, C.; Ronski, S. C.; Bohnet-Joschko, S.; Giesel, F. L.; Kopka, K.

2019

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR

Arndt, C.; Feldmann, A.; Koristka, S.; Schäfer, M.; Bergmann, R.; Metwasi, N.; Berndt, N.; Bachmann, D.; Kegler, A.; Schmitz, M.; Puentes-Cala, E.; Soto, J. A.; Ehninger, G.; Pietzsch, J.; Liolios, C.; Wunderlich, G.; Kotzerke, J.; Kopka, K.; Bachmann, M.